{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:07:26Z","timestamp":1784689646523,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1111\/jth.15883","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T10:48:55Z","timestamp":1663325335000},"page":"2921-2929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8096-0236","authenticated-orcid":false,"given":"Thure F.","family":"Overvad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2975-647X","authenticated-orcid":false,"given":"Flemming","family":"Skj\u00f8th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-5276","authenticated-orcid":false,"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5425-2383","authenticated-orcid":false,"given":"Simon","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8073-7664","authenticated-orcid":false,"given":"Anne G.","family":"Ording","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-8674","authenticated-orcid":false,"given":"Torben B.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2922-6970","authenticated-orcid":false,"given":"Peter B.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.15883_bb0010","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.amjmed.2021.01.031","article-title":"Increasing incidence and declining mortality after cancer\u2010associated venous thromboembolism: a nationwide cohort study","volume":"134","author":"Ording","year":"2021","journal-title":"Am J Med"},{"key":"10.1111\/jth.15883_bb0015","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population\u2010based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"10.1111\/jth.15883_bb0020","doi-asserted-by":"crossref","first-page":"100082","DOI":"10.1016\/j.tru.2021.100082","article-title":"Venous thromboembolism: the patient perspective","volume":"5","author":"Kevane","year":"2021","journal-title":"Thromb Update"},{"key":"10.1111\/jth.15883_bb0025","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.amjmed.2018.04.042","article-title":"Risk of recurrent venous thromboembolism: a Danish nationwide cohort study","volume":"131","author":"Albertsen","year":"2018","journal-title":"Am J Med"},{"key":"10.1111\/jth.15883_bb0030","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy\u2010associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.15883_bb0035","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1002\/onco.13596","article-title":"Update on guidelines for the management of cancer\u2010associated thrombosis","volume":"26","author":"Streiff","year":"2021","journal-title":"Oncologist"},{"key":"10.1111\/jth.15883_bb0040","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15883_bb0045","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high\u2010risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15883_bb0050","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1055\/s-0040-1712143","article-title":"Assessing full benefit of rivaroxaban prophylaxis in high\u2010risk ambulatory patients with cancer: thromboembolic events in the randomized CASSINI trial","volume":"04","author":"Khorana","year":"2020","journal-title":"TH Open"},{"key":"10.1111\/jth.15883_bb0055","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1136\/heartjnl-2020-318083","article-title":"Cardiotoxicities of novel cancer immunotherapies","volume":"107","author":"Stein\u2010Merlob","year":"2021","journal-title":"Heart"},{"key":"10.1111\/jth.15883_bb0060","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.medj.2021.02.002","article-title":"Increased incidence of venous thromboembolism with cancer immunotherapy","volume":"2","author":"Roopkumar","year":"2021","journal-title":"Med"},{"key":"10.1111\/jth.15883_bb0065","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"Moik","year":"2021","journal-title":"Blood"},{"key":"10.1111\/jth.15883_bb0070","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1111\/jth.15883_bb0075","doi-asserted-by":"crossref","first-page":"107818","DOI":"10.1016\/j.intimp.2021.107818","article-title":"Thromboembolic events associated with immune checkpoint inhibitors: A real\u2010world study of data from the food and drug administration adverse event reporting system (FAERS) database","volume":"98","author":"Li","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1111\/jth.15883_bb0080","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta\u2010analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.15883_bb0085","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/jth.15272","article-title":"Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors","volume":"19","author":"Icht","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15883_bb0090","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/ejh.13734","article-title":"Assessing the risk of thromboembolism in cancer patients receiving immunotherapy","volume":"108","author":"Goel","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1111\/jth.15883_bb0095","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11239-022-02649-x","article-title":"Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors","volume":"54","author":"Alma","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jth.15883_bb0100","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/ejh.13598","article-title":"Prognostic impact and risk factors of cancer\u2010associated thrombosis events in stage\u2010IV cancer patients treated with immune checkpoint inhibitors","volume":"106","author":"Kewan","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1111\/jth.15883_bb0105","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/bloodadvances.2021006484","article-title":"Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy","volume":"6","author":"Overvad","year":"2022","journal-title":"Blood Adv"},{"key":"10.1111\/jth.15883_bb0110","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish Civil Registration System as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur J Epidemiol"},{"key":"10.1111\/jth.15883_bb0115","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"key":"10.1111\/jth.15883_bb0120","article-title":"Data resource profile: the Danish national prescription registry","volume":"46","author":"Potteg\u00e5rd","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1111\/jth.15883_bb0125","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/CLEP.S245060","article-title":"Existing data sources in clinical epidemiology: laboratory information system databases in Denmark","volume":"12","author":"Arendt","year":"2020","journal-title":"Clin Epidemiol"},{"key":"10.1111\/jth.15883_bb0130","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1111\/jth.15883_bb0135","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/EDE.0000000000001208","article-title":"Validity of antineoplastic procedure codes in the Danish national patient registry: the case of colorectal cancer","volume":"31","author":"Broe","year":"2020","journal-title":"Epidemiology"},{"key":"10.1111\/jth.15883_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012832","article-title":"Positive predictive value of cardiovascular diagnoses in the Danish national patient registry: a validation study","volume":"6","author":"Sundb\u00f8ll","year":"2016","journal-title":"BMJ Open"},{"key":"10.1111\/jth.15883_bb0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/CLEP.S50449","article-title":"Registration of acute stroke: validity in the Danish Stroke Registry and the Danish National Registry of Patients","volume":"6","author":"Wildenschild","year":"2013","journal-title":"Clin Epidemiol"},{"key":"10.1111\/jth.15883_bb0150","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/1403494817716582","article-title":"Predictive value of stroke discharge diagnoses in the Danish National Patient Register","volume":"45","author":"L\u00fchdorf","year":"2017","journal-title":"Scand J Public Health"},{"key":"10.1111\/jth.15883_bb0155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000102143","article-title":"Validity of stroke diagnoses in a national register of patients","volume":"28","author":"Krarup","year":"2007","journal-title":"Neuroepidemiology"},{"key":"10.1111\/jth.15883_bb0160","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jclinepi.2008.03.005","article-title":"Predictive values of acute coronary syndrome discharge diagnoses differed in the Danish National Patient Registry","volume":"62","author":"Joensen","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/jth.15883_bb0165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1536867X0400400201","article-title":"Cumulative incidence estimation in the presence of competing risks","volume":"4","author":"Coviello","year":"2004","journal-title":"Stata J"},{"key":"10.1111\/jth.15883_bb0170","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine\u2010Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"10.1111\/jth.15883_bb0175","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaccao.2021.03.001","article-title":"Venous and arterial thromboembolism in patients with cancer","volume":"3","author":"Gervaso","year":"2021","journal-title":"JACC CardioOncology"},{"key":"10.1111\/jth.15883_bb0180","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/jth.13594","article-title":"Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer: comment","volume":"15","author":"Noble","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15883_bb0185","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2217\/imt-2021-0151","article-title":"Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors","volume":"14","author":"Kartolo","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1111\/jth.15883_bb0190","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thromres.2021.06.018","article-title":"Venous thrombotic events in patients treated with immune checkpoint inhibitors for non\u2010small cell lung cancer: a retrospective multicentric cohort study","volume":"205","author":"Desch\u00eanes\u2010Simard","year":"2021","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15883_bb0195","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1160\/TH17-03-0171","article-title":"Rivaroxaban for preventing venous thromboembolism in high\u2010risk ambulatory patients with cancer: Rationale and design of the CASSINI trial","volume":"117","author":"Khorana","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15883_bb0200","unstructured":"Angelini D, Ashrani A, Elshoury A, Fanikos J, Fertrin K, Fogerty AE, Gangaraju R, Gao S, Goldhaber SZ, Gundabolu K, Ibrahim I, Kraut E, Leavitt AD, Lee A, Lee JT, Lim M, Mann J, Martin K, McMahon B, Moriarty J, et al. NCCN guidelines version 1. 2022 cancer\u2010associated venous thromboembolic disease; 2022."},{"key":"10.1111\/jth.15883_bb0205","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1111\/jth.15883_bb0210","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.15883_bb0215","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID\u201019","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1111\/jth.15883_bb0220","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15883_bb0225","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/onco.13540","article-title":"D\u2010dimer enhances risk\u2010targeted thromboprophylaxis in ambulatory patients with cancer","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"key":"10.1111\/jth.15883_bb0230","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.3390\/cancers14081937","article-title":"In search of the appropriate anticoagulant\u2010associated bleeding risk assessment model for cancer\u2010associated thrombosis patients","volume":"14","author":"Po\u00e9nou","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1111\/jth.15883_bb0235","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1186\/s12889-015-2670-9","article-title":"Evidence for the low recording of weight status and lifestyle risk factors in the Danish National Registry of Patients, 1999\u20132012","volume":"15","author":"S\u00f8gaard","year":"2015","journal-title":"BMC Public Health"},{"key":"10.1111\/jth.15883_bb0240","unstructured":"Rasmussen MS, Dorff MH, Holt MI, Grove EL, Hvas AM. Cancer and Venous Thromboembolism. Guideline by Danish Society of Thrombosis and Haemostasis and Danish Society of Clinical Oncology. 2017."},{"key":"10.1111\/jth.15883_bb0245","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/jth.15250","article-title":"Pulmonary embolism at autopsy in cancer patients","volume":"19","author":"Gimbel","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15883_bb0250","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA\u2010approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1111\/jth.15883_bb0255","first-page":"381.e1","article-title":"Venous thromboembolism risk in patients receiving neoadjuvant chemotherapy for bladder cancer","volume":"40","author":"Garas","year":"2022","journal-title":"Urol Oncol Semin Orig Invest"},{"key":"10.1111\/jth.15883_bb0260","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejca.2020.07.005","article-title":"Clinically significant bleeding with immune checkpoint inhibitors: a retrospective cohort study","volume":"137","author":"Kewan","year":"2020","journal-title":"Eur J Cancer"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15883","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15883","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622183716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622183716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:37:15Z","timestamp":1761536235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622183716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1538783622183716"],"URL":"https:\/\/doi.org\/10.1111\/jth.15883","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The Authors. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}